Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Opto-acoustic imaging of drug discovery biomarkers.
Curr. Pharm. Biotechnol. 13, 2117-2127 (2012)
Optical imaging has seen significant developments over the past decade as an investigational tool for in-vivo visualization of cellular and sub-cellular events. With the recent addition of optoacoustic (photoacoustic) methods, in particular multi-spectral opto-acoustic tomography (MSOT), to the already rich armamentarium of photonic methods the capacity of optical molecular imaging across scales has widened significantly. MSOT brings unique features into optical imaging, namely high resolution optical imaging over several millimeters to centimeters of tissue depth and the ability to simultaneously resolve multiple tissue molecules and extrinsically administered optical or optoacoustic agents with physiological or molecular specificity. Here, we discuss the implications of utilizing MSOT in the context of drug discovery and review suitable optoacoustic agents against disease and drug efficacy biomarkers. The combination of existing knowledge on generating optical targeted contrast, with the high resolution deep tissue visualization offered by MSOT, allows for the development of next-generation biological optical imaging and corresponding drug discovery applications.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Times Cited
Altmetric
2.805
1.078
6
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Review
Schlagwörter
Biomarkers ; Fluorochromes ; Imaging ; Optoacoustic ; Msot; RED FLUORESCENT PROTEIN; INFRARED MOLECULAR PROBE; RESEARCH-AND-DEVELOPMENT; IN-VIVO; BREAST-CANCER; SMALL ANIMALS; PHOTOACOUSTIC TOMOGRAPHY; CLINICAL BIOMARKERS; TUMOR XENOGRAFTS; ENERGY-TRANSFER
Sprache
englisch
Veröffentlichungsjahr
2012
HGF-Berichtsjahr
2012
ISSN (print) / ISBN
1389-2010
e-ISSN
1873-4316
Zeitschrift
Current Pharmaceutical Biotechnology
Quellenangaben
Band: 13,
Heft: 11,
Seiten: 2117-2127
Verlag
Bentham Science Publishers
Begutachtungsstatus
Peer reviewed
POF Topic(s)
30205 - Bioengineering and Digital Health
Forschungsfeld(er)
Enabling and Novel Technologies
PSP-Element(e)
G-505500-001
PubMed ID
22335481
WOS ID
WOS:000308071600003
Erfassungsdatum
2012-09-27